Insulin resistance arises from disruptions in metabolic communication involving nutrient exposure, microbial metabolism, and host endocrine responses. A revised Microbiome-Metabolokine-Adipokine (MMA) Axis is proposed to link gut microbial metabolic signals with responses in the intestine, liver, and adipose tissue.
The MMA Axis
Microbiome-derived signals, such as short-chain fatty acids and tryptophan-derived metabolites, can affect intestinal signaling, incretin secretion, hepatic nutrient sensing, and adipose lipid buffering, ultimately influencing insulin sensitivity. Within this network, fibroblast growth factor 21 (FGF21) and growth differentiation factor 15 (GDF15) are considered distinct adaptive endocrine signals. FGF21 primarily responds to nutrient and metabolic stress, while GDF15 communicates broader cellular stress.
Understanding Insulin Resistance
Elevated levels of either metabolokine during insulin resistance do not necessarily indicate endocrine resistance. Progression toward insulin resistance reflects a mismatch between metabolic stress and the ability of integrated endocrine responses to maintain metabolic flexibility. Current evidence supports individual signaling modules, but a direct sequence has not been established. This revised framework provides a basis for investigating how microbiome-derived signals interact with host endocrine adaptation during insulin resistance development.